BR112019025381A2 - Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal - Google Patents

Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal Download PDF

Info

Publication number
BR112019025381A2
BR112019025381A2 BR112019025381-5A BR112019025381A BR112019025381A2 BR 112019025381 A2 BR112019025381 A2 BR 112019025381A2 BR 112019025381 A BR112019025381 A BR 112019025381A BR 112019025381 A2 BR112019025381 A2 BR 112019025381A2
Authority
BR
Brazil
Prior art keywords
christmas
post
treat
prevent
anxiety
Prior art date
Application number
BR112019025381-5A
Other languages
English (en)
Inventor
Arthur Mitchell Edwin
Slykerman Rebecca
Villiers Stanley Thorsten
Original Assignee
University Of Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Otago filed Critical University Of Otago
Publication of BR112019025381A2 publication Critical patent/BR112019025381A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pediatric Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a métodos para tratar ou prevenir pelo menos uma dentre depressão pós-natal (pnd) e ansiedade pós-natal (pna), e riscos e sequelas das mesmas, administrando-se lactobacillus rhamnosus hn001 ou derivados do mesmo e, adicionalmente, usos, composições e medicamentos que compreendem lactobacillus rhamnosus hn001 ou derivados do mesmo, para tratar ou prevenir pelo menos uma dentre pnd e pna, e riscos e sequelas das mesmas.
BR112019025381-5A 2017-06-02 2017-06-02 Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal BR112019025381A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/053263 WO2018220429A1 (en) 2017-06-02 2017-06-02 Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety

Publications (1)

Publication Number Publication Date
BR112019025381A2 true BR112019025381A2 (pt) 2020-06-16

Family

ID=64454470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025381-5A BR112019025381A2 (pt) 2017-06-02 2017-06-02 Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal

Country Status (14)

Country Link
US (1) US11439674B2 (pt)
EP (1) EP3634447A4 (pt)
JP (1) JP7210032B2 (pt)
KR (1) KR102591869B1 (pt)
CN (1) CN110913879A (pt)
AU (1) AU2017416677B2 (pt)
BR (1) BR112019025381A2 (pt)
CA (1) CA3065903C (pt)
MX (1) MX2019014418A (pt)
MY (1) MY197900A (pt)
NZ (1) NZ759766A (pt)
PH (1) PH12019502725A1 (pt)
RU (1) RU2763172C2 (pt)
WO (1) WO2018220429A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
CN109125357A (zh) * 2018-10-24 2019-01-04 南京益恒寿生命科技有限公司 一种治疗肠易激综合症的益生菌－粪菌液复合液
KR102148707B1 (ko) * 2019-02-22 2020-08-31 한국식품연구원 우울증 및 불안장애의 예방, 개선 또는 치료 효능을 갖는 김치 유산균 락토바실러스 사케아이
WO2020250040A1 (en) * 2019-06-14 2020-12-17 Compagnie Gervais Danone Composition for amelioration of anxiety and/or stress
FR3098396B1 (fr) * 2019-07-10 2022-07-29 Indigo Therapeutics Composition pour le traitement des troubles des émotions
WO2023111270A1 (en) * 2021-12-16 2023-06-22 Biopolis, S. L. Use of postbiotics in the treatment and/or prevention of anxiety disorders
CN115400155A (zh) * 2022-08-17 2022-11-29 中南大学 缓解产后抑郁的益生菌组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2241616T3 (da) * 1997-08-21 2013-02-18 New Zealand Dairy Board Immunitetsforbedrende mælkesyrebakterier
US20110077044A1 (en) 2008-08-20 2011-03-31 Qualcomm Incorporated Power control for wireless lan stations
CN102202527B (zh) * 2008-11-03 2014-12-31 雀巢产品技术援助有限公司 包含益生菌并改善睡眠模式的营养组合物
CA2744778C (en) * 2008-11-28 2019-01-15 University Of Otago Use of lactic acid bacteria to treat or prevent eczema
ES2569241T5 (es) * 2010-01-19 2019-09-11 Abbott Lab Una composición que comprende Lactobacillus rhamnosus HN001 y prebióticos para su uso en el tratamiento de la enfermedad pulmonar alérgica
CN101791125B (zh) * 2010-01-29 2012-07-25 中国科学院南海海洋研究所 一种促进产后妇女泌乳及恢复的功能营养品及其制备方法
CN102994432B (zh) 2012-12-26 2014-07-09 光明乳业股份有限公司 一种鼠李糖乳杆菌及其用途
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
WO2016198528A1 (en) 2015-06-11 2016-12-15 Nestec S.A. Dietary supplement
EP3478306B1 (en) * 2016-07-01 2023-11-01 Société des Produits Nestlé S.A. Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and depression in a mammal

Also Published As

Publication number Publication date
PH12019502725A1 (en) 2020-07-13
NZ759766A (en) 2022-09-30
US11439674B2 (en) 2022-09-13
WO2018220429A1 (en) 2018-12-06
JP7210032B2 (ja) 2023-01-23
KR20200032048A (ko) 2020-03-25
CA3065903C (en) 2023-01-24
US20200188454A1 (en) 2020-06-18
RU2019144344A3 (pt) 2021-07-09
MX2019014418A (es) 2020-02-24
MY197900A (en) 2023-07-24
CN110913879A (zh) 2020-03-24
AU2017416677A1 (en) 2020-01-02
CA3065903A1 (en) 2018-12-06
KR102591869B1 (ko) 2023-10-19
JP2020528401A (ja) 2020-09-24
AU2017416677B2 (en) 2022-09-29
RU2763172C2 (ru) 2021-12-28
RU2019144344A (ru) 2021-07-09
EP3634447A1 (en) 2020-04-15
EP3634447A4 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
BR112019025381A2 (pt) Uso de bactérias de ácido láctico para tratar ou prevenir pelo menos uma dentre depressão pós-natal e ansiedade pós-natal
BR112018015097A2 (pt) composição e reatores
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
CY1123735T1 (el) Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015027536A2 (pt) composição compreendendo mistura de bactérias ácidas lácticas, bem como uso da referida mistura
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
BR112016029894A2 (pt) método para aumentar o ganho de peso e/ou melhorar a razão de corversão de alimentos de animais de fazenda, e, uso de uma ou mais enzimas protolíticas em combinação com pelo menos uma fitase no alimento para animais.
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112017006416A2 (pt) composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico
BR112017000978A2 (pt) mioinositol e probióticos e usos
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112015025733A2 (pt) composição compreendendo uma combinação de um ex-trato de sabugueiro e uma estirpe de lactobacillus rhamnosus

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]